533 Pembrolizumab With or Without Vismodegib for Advanced Basal Cell Carcinoma: An Investigator-Initiated, Proof-Of-Concept Study

Journal of Investigative Dermatology- United Kingdom

doi 10.1016/j.jid.2019.03.609

Full Text

Abstract

Available in

Date

Authors

Publisher

Elsevier BV

Related search

Vismodegib and Orbital Excision for Treating Locally Advanced Basal Cell Carcinoma

International Medical Case Reports Journal
Medicine
2018English

035 Experiences With Smo Antagonist Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2017English

Vismodegib for Periocular and Orbital Basal Cell Carcinoma

JAMA Ophthalmology
Ophthalmology
2013English

Vismodegib for Giant, Locally Advanced, Basal Cell Carcinoma and Its Complex Position in Clinical Practice

JAAD Case Reports
Dermatology
2019English

Lack of Response to Vismodegib in a Patient With Advanced Basal Cell Carcinoma: A Case Report

Journal of Clinical & Experimental Oncology
2017English

Granulation Tissue Masquerading as Basal Cell Carcinoma After Treatment With Vismodegib

JAAD Case Reports
Dermatology
2018English

Correction To: Long-Term Safety and Efficacy of Vismodegib in Patients With Advanced Basal Cell Carcinoma: Final Update of the Pivotal ERIVANCE BCC Study

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Basal Cell Cancer Treatment. Therapeutic Experience With Vismodegib Therapy

Medical Council
2018English

Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus

JAMA Oncology
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy